Legal Representation
Attorney
Kirk M. Miles
USPTO Deadlines
Next Deadline
37 days remaining
Abandonment Notice E-Mailed - Failure to Respond
Due Date
January 21, 2026
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 21, 2025 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Nov 21, 2025 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Aug 7, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 7, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 7, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 5, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 3, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 3, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 3, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
(Based on Intent to Use) Nutraceuticals for the treatment of building muscle mass, weight loss, increasing sexual performance, recovery from workouts and injuries, and increasing an individual’s energy
Class 044
(Based on Use in Commerce) Semaglutide and tirzepatide injection therapy services; testosterone replacement therapy services; peptide therapy services; nutrient therapy services
First Use Anywhere:
Mar 31, 2023
First Use in Commerce:
Mar 31, 2023
Classification
International Classes
005
044